Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

EDIT 01.06.2025

SERA-AI Powered Highlights
Date of Upcoming Event:2025-01-15
Name of Upcoming Event:43rd Annual J.P. Morgan Healthcare Conference
Full Press ReleaseSEC FilingsOur EDIT Tweets

About Gravity Analytica

Recent News

  • 01.15.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.13.2025 - Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities
  • 01.06.2025 - Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Recent Filings

  • 01.13.2025 - EX-99.1 EX-99.1
  • 01.13.2025 - 8-K Current report
PDF Version

CAMBRIDGE, Mass.,Jan. 06, 2025(GLOBE NEWSWIRE) --Editas Medicine, Inc.(Nasdaq: EDIT), a leading gene editing company, today announced that the Company’s President and CEOGilmore O’Neill, M.B.,M.M.Sc., will present at the 43rd AnnualJ.P. Morgan Healthcare ConferenceonWednesday, January 15, 2025,11:15 a.m. PT/2:15 p.m. ETinSan Francisco, CA.

Alive webcastof the presentation will be available on the “Investors” section of theEditas Medicinewebsite atwww.editasmedicine.com. An archived replay will be available on the website for approximately 30 days following the presentation.

AboutEditas MedicineAs a leading gene editing company,Editas Medicineis focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline ofin vivomedicines for people living with serious diseases around the world.Editas Medicineaims to discover, develop, manufacture, and commercialize transformative, durable, precisionin vivogene editing medicines for a broad class of diseases.Editas Medicineis the exclusive licensee of Broad Institute’s Cas12a patent estate andBroad Instituteand Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visitwww.editasmedicine.com.

Media and Investor Contact:ir@editasmed.com

Primary Logo

Source: Editas Medicine, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com